The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone | Zendy

Andrew Wardley | Zendy; Gordon C. Jayson | Zendy; DJ Goldsmith | Zendy; Michael Venning | Zendy; P. Ackrill | Zendy; J H Scarffe | Zendy

Open Access

The treatment of nephrotic syndrome caused by primary (light chain) amyloid with vincristine, doxorubicin and dexamethasone

Author(s) -

Andrew Wardley,

Gordon C. Jayson,

DJ Goldsmith,

Michael Venning,

P. Ackrill,

J H Scarffe

Publication year - 1998

Publication title -

british journal of cancer

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.833

H-Index - 236

eISSN - 1532-1827

pISSN - 0007-0920

DOI - 10.1038/bjc.1998.577

Subject(s) - nephrotic syndrome , dexamethasone , vincristine , medicine , doxorubicin , regimen , gastroenterology , oncology , chemotherapy , cyclophosphamide

Three out of four patients with primary (light chain) amyloid nephrotic syndrome treated with vincristine, doxorubicin and dexamethasone (VAD) induction obtained a partial response and are alive in continuing remission at 4.1, 6.5 and 9.3 years. These preliminary results are of considerable interest and suggest that prospective evaluation of this regimen is warranted in patients with this condition.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research